1
|
Draper B, Yee WL, Pedrana A, Kyi KP, Qureshi H, Htay H, Naing W, Thompson AJ, Hellard M, Howell J. Reducing liver disease-related deaths in the Asia-Pacific: the important role of decentralised and non-specialist led hepatitis C treatment for cirrhotic patients. THE LANCET REGIONAL HEALTH. WESTERN PACIFIC 2022; 20:100359. [PMID: 35024676 PMCID: PMC8733182 DOI: 10.1016/j.lanwpc.2021.100359] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Affiliation(s)
- Bridget Draper
- Disease Elimination Program, Burnet Institute Melbourne, Australia.,School of Public Health and Preventive Medicine, Monash University Melbourne, Australia
| | | | - Alisa Pedrana
- Disease Elimination Program, Burnet Institute Melbourne, Australia.,School of Public Health and Preventive Medicine, Monash University Melbourne, Australia.,Health Services Research and Implementation, Monash Partners, Melbourne, Australia
| | | | - Huma Qureshi
- Gastroenterologist, Doctors Plaza, Clifton, Karachi, Pakistan
| | - Hla Htay
- Burnet Institute Yangon, Myanmar
| | - Win Naing
- Myanmar Liver Foundation.,Yangon Specialty Hospital, Myanmar
| | - Alexander J Thompson
- St Vincent's Hospital Melbourne, Australia.,Department of Medicine, University of Melbourne, Australia
| | - Margaret Hellard
- Disease Elimination Program, Burnet Institute Melbourne, Australia.,School of Public Health and Preventive Medicine, Monash University Melbourne, Australia.,Hepatitis Services, Department of Infectious Diseases Alfred Hospital Melbourne Australia.,Doherty Institute, Melbourne, Australia.,School of Population and Global Health, University of Melbourne, Australia
| | - Jessica Howell
- Disease Elimination Program, Burnet Institute Melbourne, Australia.,School of Public Health and Preventive Medicine, Monash University Melbourne, Australia.,St Vincent's Hospital Melbourne, Australia.,Department of Medicine, University of Melbourne, Australia
| |
Collapse
|
3
|
Tripathi K, Loganathan S, Trivedi N, Abraham GM. Impact of hepatitis C remission on glycemic control in patients with type 2 diabetes mellitus: primary care outpatient experience. J Community Hosp Intern Med Perspect 2021; 11:354-356. [PMID: 34234905 PMCID: PMC8118393 DOI: 10.1080/20009666.2021.1886631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Kartikeya Tripathi
- Department of Gastroenterology and Hepatology, University of Massachusetts Medical School- Baystate Springfield, MA
| | | | - Nitin Trivedi
- Department of Medicine, St Vincent Hospital, Worcester, MA.,Department of Medicine, University of Massachusetts, Worcester, MA
| | - George M Abraham
- Department of Medicine, St Vincent Hospital, Worcester, MA.,Department of Medicine, University of Massachusetts, Worcester, MA
| |
Collapse
|
4
|
Forns X, Feld JJ, Dylla DE, Pol S, Chayama K, Hou J, Heo J, Lampertico P, Brown A, Bondin M, Tatsch F, Burroughs M, Marcinak J, Zhang Z, Emmett A, Gordon SC, Jacobson IM. Safety of Patients with Hepatitis C Virus Treated with Glecaprevir/Pibrentasvir from Clinical Trials and Real-World Cohorts. Adv Ther 2021; 38:3409-3426. [PMID: 34021887 PMCID: PMC8189955 DOI: 10.1007/s12325-021-01753-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 04/18/2021] [Indexed: 12/24/2022]
Abstract
Introduction More than 70 million people are estimated to be infected with hepatitis C virus (HCV) globally. If left untreated, HCV infection can lead to complications such as extensive liver fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). Evolution of treatments has resulted in highly effective and well-tolerated all-oral direct-acting antivirals. The pangenotypic regimen of glecaprevir/pibrentasvir is approved for treating HCV for patients without cirrhosis or with compensated cirrhosis (CC). Guidelines have evolved to simplify treatment to enable non-specialists to manage and treat HCV-infected patients. Simultaneously, such treatment algorithms provide guidance on the pretreatment identification of small subsets of patients who may require specialist treatment and long-term follow-up for advanced liver disease, including those at risk of developing HCC. This study describes the safety profile of glecaprevir/pibrentasvir in patients identified using previously described noninvasive laboratory measures who may be eligible for treatment by non-liver specialists. Methods This post hoc analysis of glecaprevir/pibrentasvir in patients, identified by noninvasive laboratory measures, intended to exclude patients with advanced liver disease and severe renal impairment, who can be managed within non-liver specialist settings. Patients were included from clinical trials and real-world studies of glecaprevir/pibrentasvir for HCV treatment. Baseline demographics, clinical characteristics, and safety assessments, including adverse events and laboratory abnormalities, were summarized. Results Data across these large-scale studies confirm that glecaprevir/pibrentasvir is well tolerated across different patient populations, with fewer than 0.1% of patients experiencing a serious adverse event related to treatment drugs, and few patients developing HCC during or after treatment. Conclusion The safety profile of glecaprevir/pibrentasvir enhances the confidence of non-liver specialists to treat the majority of HCV-infected patients, and provides an opportunity to expand the treater pool, potentially increasing diagnosis and treatment rates for HCV, contributing to elimination of HCV. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-021-01753-3.
Collapse
Affiliation(s)
- Xavier Forns
- Liver Unit, Hospital Clinic de Barcelona, IDIBAPS and CIBEREHD, University of Barcelona, Barcelona, Spain.
| | - Jordan J Feld
- Toronto Centre for Liver Disease, University Health Network, University of Toronto, Toronto, ON, Canada
| | | | - Stanislas Pol
- Liver Unit, Cochin Hospital, APHP, Inserm U-1223, Institut Pasteur, Université de Paris, Paris, France
| | - Kazuaki Chayama
- Department of Gastroenterology and Metabolism, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan
| | - Jinlin Hou
- Department of Infectious Diseases, State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Nanfang Hospital, Southern Medical University, Guangzhou, China
| | - Jeong Heo
- Department of Internal Medicine, College of Medicine, Pusan National University and Medical Research Institute, Busan, Republic of Korea
| | - Pietro Lampertico
- Division of Gastroenterology and Hepatology, CRC "A.M. and A. Migliavacca" Center for Liver Disease, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy
- Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy
| | - Ashley Brown
- Imperial College Healthcare NHS Trust, London, UK
| | | | | | | | | | | | | | - Stuart C Gordon
- Division of Gastroenterology and Hepatology, Henry Ford Health System and Wayne State University School of Medicine, Detroit, MI, USA
| | | |
Collapse
|
6
|
Sinha MK, Raghuwanshi B, Mishra B. Menace of Hepatitis C virus among multitransfused thalassemia patients in Balasore district of Odisha state in India. J Family Med Prim Care 2019; 8:2850-2854. [PMID: 31681654 PMCID: PMC6820385 DOI: 10.4103/jfmpc.jfmpc_449_19] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Revised: 06/19/2019] [Accepted: 07/12/2019] [Indexed: 02/01/2023] Open
Abstract
CONTEXT Hepatitis C virus (HCV) is a potential cause of morbidity and mortality worldwide. It is most commonly transmitted through injecting drug use; the reuse or inadequate sterilization of medical equipment and the transfusion of unscreened blood products. Management of thalassemia requires long-term blood transfusion. Though it improves the overall survival, it carries a definite risk of infection which is expected to be higher in resource limited settings. AIMS To find the percentage of transfusion-transmitted infections (TTIs) in multitransfused patients of thalassemia in Eastern India. SETTINGS AND DESIGN The study was conducted to assess blood safety in rural population in India by measuring the percentage of TTIs including HCV in multitransfused thalassemia patients. METHODS AND MATERIALS One hundred and twenty three patients with major beta-thalassemia were enrolled in this study. The blood samples were tested using ELISA technique for all TTIs. HIV fourth generation kits, HbsAg, HCV third generation kits, malaria and syphilis, parbovirus IgM and parbovirus IgG kits, HEV Antigen and IgM antibody were used. STATISTICAL ANALYSIS USED Proportions and means were calculated for categorical and continuous variables, respectively. Chi-square test was applied and P value of <0.05 was taken as significant. RESULTS The mean age of patients was 9.5 years ± 5.2 years. Among various TTIs, Hepatitis C and HIV was prevalent among 59.3% and 4.1% of the study participants, respectively. CONCLUSIONS The causes of high prevalence of HCV may be due to donors being usually asymptomatic in early stages, despite being screened for HCV possibly due to missing early window period infections. The screening methodology of TTIs particularly HCV at the district and village level and consequent increased prevalence of HCV in multitransfused rustic population of India shows the extent of blood safety.
Collapse
Affiliation(s)
- Mithilesh K. Sinha
- Department of Surgery, All India Institute of Medical Sciences, Bhubaneshwar, Odisha, India
| | - Babita Raghuwanshi
- Department of Transfusion Medicine and Blood Bank, All India Institute of Medical Sciences, Bhopal, Madhya Pradesh, India
| | - Bijayanimala Mishra
- Department of Microbiology, All India Institute of Medical Sciences, Bhubaneshwar, Odisha, India
| |
Collapse
|
7
|
Caring for patients with chronic hepatitis C infection. Nursing 2019; 49:36-42. [PMID: 30720670 DOI: 10.1097/01.nurse.0000553271.39804.a4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
Hepatitis C virus (HCV) infection is the most common chronic bloodborne infection in the US. This article discusses the pathophysiology of HCV infection, new treatment options, and nursing care and patient teaching for patients with chronic HCV infection.
Collapse
|